Jacobsson H, Viland H, Blomgren H
Department of Diagnostic Radiology, Karolinska Hospital, Stockholm, Sweden.
Int J Immunopharmacol. 1993 Apr;15(3):353-60. doi: 10.1016/0192-0561(93)90046-2.
Experiments have been conducted in mice to examine whether treatment with the immunostimulating drug RU 41,740 (Biostim) may change the distribution of i.v. injected radiolabelled human albumin colloids. It was observed that a single i.p. injection of Biostim (1 ng-1000 micrograms) significantly enhanced trapping of the particles in spleen and lungs. The effect, which was dose-dependent, was most pronounced in the lungs where more than a 10-fold increase could take place. On the contrary, oral administration of Biostim caused a dose-dependent decrease of colloid trapping in the lungs. Further experiments showed that oral administration of Biostim resulted in the appearance of soluble factors in the blood which inhibited the phagocytic activity of lung macrophages, for example, sera from such mice inhibited lung colloid trapping when injected into new hosts. I.p. administration of Biostim, however, resulted in the appearance of factors in the blood which enhanced phagocytosis of lung macrophages. Our conclusion is that the biological activity of Biostim in vivo may be highly dependent on its route of administration.
已在小鼠身上进行实验，以研究用免疫刺激药物RU 41,740（生物刺激素）治疗是否会改变静脉注射放射性标记的人白蛋白胶体的分布。据观察，单次腹腔注射生物刺激素（1纳克至1000微克）可显著增强脾脏和肺部对颗粒的捕获。这种效应呈剂量依赖性，在肺部最为明显，肺部的捕获量可增加10倍以上。相反，口服生物刺激素会导致肺部胶体捕获量呈剂量依赖性下降。进一步的实验表明，口服生物刺激素会导致血液中出现可溶性因子，这些因子会抑制肺巨噬细胞的吞噬活性，例如，将此类小鼠的血清注射到新宿主中时，会抑制肺部胶体捕获。然而，腹腔注射生物刺激素会导致血液中出现增强肺巨噬细胞吞噬作用的因子。我们的结论是，生物刺激素在体内的生物活性可能高度依赖于其给药途径。
